How Do You Keep Moving When the World Stands Still?

The urgency to develop better therapies for renal and adjacent diseases never quits. That's why when the pandemic hit, we worked even harder to find solutions. Our proactive approach enabled us to continue work at our sites, moving research forward.

During the COVID-19 slowdown, we've been preemptive — adapting so research could continue while planning for the resumption of full-capacity clinical trial activity. By modifying processes and thoroughly preparing every research segment — patients, sites, sponsors and our staff — we are prepared to lead the return to full-scale clinical research. Frenova Knows the importance of leveraging our expertise and tenacity to advance nephrology research.

FRENOVA **KNOWS**

Frenova® Renal Research

How Do You Keep Studies Progressing When All Signs Point to Stop? FRENOVA **KNOWS**

What we've been doing:

- Adapting rapidly to maintain patient retention for current studies
- Further optimizing the use of prescreening data to enhance patient identification for new patient enrollment
- Evaluating COVID-19 incidences across sites to determine the best areas in which to focus enrollment efforts
- Providing proactive and increased communications to ensure that trials stay on track
- Using CDC, FDA and local guidelines to properly accommodate patients who tested positive for COVID-19

> **Frenova guided us through sensible steps, ensuring the study progressed despite the global pandemic, while also keeping patient safety at the forefront. The Frenova team was fully engaged, motivated, proactive and supportive.**
>
> **CHARLES BRADLEY**, VP Clinical Development and Clinical Operations — FibroGen

> **In the face of challenges presented by the pandemic, Frenova worked diligently and creatively to ensure the quality of our studies did not suffer. The Frenova team embraced this period to position themselves as thought leaders and actively prepare for a return to a new research environment.**
>
> **ASHLEY H. JOHNS**, VP of Clinical Operations, inRegen

Moving forward, we will continue to:

- Be agile, adapting alternative solutions to meet your trial's needs in a shifting environment
- Provide the managed investigator sites, patients and data you need to achieve your enrollment goals
- Provide creative patient outreach solutions such as telehealth, home health visits and eConsent